Quercetin alleviates hyperoxia-induced bronchopulmonary dysplasia by inhibiting ferroptosis through the MAPK/PTGS2 pathway: Insights from network pharmacology, molecular docking, and experimental evaluations

Chem Biol Drug Des. 2024 Apr;103(4):e14520. doi: 10.1111/cbdd.14520.

Abstract

Quercetin, a bioactive natural compound renowned for its potent anti-inflammatory, antioxidant, and antiviral properties, has exhibited therapeutic potential in various diseases. Given that bronchopulmonary dysplasia (BPD) development is closely linked to inflammation and oxidative stress, and quercetin, a robust antioxidant known to activate NRF2 and influence the ferroptosis pathway, offers promise for a wide range of age groups. Nonetheless, the specific role of quercetin in BPD remains largely unexplored. This study aims to uncover the target role of quercetin in BPD through a combination of network pharmacology, molecular docking, computer analyses, and experimental evaluations.

Keywords: PTGS2; bronchopulmonary dysplasia; ferroptosis; hyperoxia; quercetin.

MeSH terms

  • Animals
  • Animals, Newborn
  • Antioxidants
  • Bronchopulmonary Dysplasia* / drug therapy
  • Bronchopulmonary Dysplasia* / metabolism
  • Cyclooxygenase 2
  • Ferroptosis*
  • Humans
  • Hyperoxia* / drug therapy
  • Hyperoxia* / metabolism
  • Infant, Newborn
  • Molecular Docking Simulation
  • Network Pharmacology
  • Quercetin / pharmacology
  • Quercetin / therapeutic use

Substances

  • Quercetin
  • Cyclooxygenase 2
  • Antioxidants
  • PTGS2 protein, human